User profiles for Siamak Moghadam-Kia

Siamak Moghadam-Kia, MD, MPH

University of Pittsburgh Medical Center
Verified email at upmc.edu
Cited by 2288

Prevention and treatment of systemic glucocorticoid side effects

S MoghadamKia, VP Werth - International journal of …, 2010 - Wiley Online Library
Background Systemic glucocorticoids are used in dermatologic practice for various diseases
including connective tissue disorders, bullous diseases, and many other dermatologic …

Positron emission tomography as a diagnostic tool in infection: present role and future possibilities

S Basu, T Chryssikos, S Moghadam-Kia… - Seminars in nuclear …, 2009 - Elsevier
The past decade has witnessed the emergence of yet another promising application of 18 F-fluorodeoxyglucose
positron emission tomography (FDG-PET) imaging in the detection and …

Anti–melanoma differentiation–associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic …

S MoghadamKia, CV Oddis, S Sato… - Arthritis care & …, 2016 - Wiley Online Library
Objective Clinically amyopathic dermatomyositis (CADM) is a subset of dermatomyositis (DM)
presenting with the characteristic rash of DM without objective muscle weakness. Asian …

[HTML][HTML] Approach to asymptomatic creatine kinase elevation

S Moghadam-Kia, CV Oddis… - Cleveland Clinic journal of …, 2016 - ncbi.nlm.nih.gov
How to manage a patient who has an elevated serum creatine kinase (CK) level but no or
insignificant muscle-related signs and symptoms is a clinical conundrum. The authors provide …

Quality of life in cutaneous lupus erythematosus

R Klein, S Moghadam-Kia, L Taylor, C Coley… - Journal of the American …, 2011 - Elsevier
BACKGROUND: Little is known about quality of life in patients with cutaneous lupus erythematosus.
OBJECTIVE: We sought to determine how cutaneous lupus affects quality of life and …

Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus

R Klein, S Moghadam-Kia, J LoMonico… - Archives of …, 2011 - jamanetwork.com
Objective To determine how to use the Cutaneous Lupus Erythematosus Disease Area and
Severity Index (CLASI) to classify patients according to disease severity (mild, moderate, and …

Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis

S Moghadam-Kia, CV Oddis, S Sato… - The Journal of …, 2017 - jrheum.org
Objective. To determine the clinical features associated with the antimelanoma
differentiation-associated gene 5 antibody (anti-MDA5) in US patients with clinically amyopathic …

Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib

S Moghadam-Kia, D Charlton, R Aggarwal… - …, 2019 - academic.oup.com
Objectives Some patients with cutaneous DM demonstrate incomplete responses to conventional
therapy while some, including those with extra-cutaneous manifestations, experience …

Risk factors and cancer screening in myositis

S Moghadam-Kia, CV Oddis… - Rheumatic …, 2020 - rheumatic.theclinics.com
The idiopathic inflammatory myopathies (IIMs) are a group of heterogeneous, systemic
autoimmune rheumatic diseases that include adult polymyositis (PM), adult dermatomyositis (DM)…

Anti-MDA5 antibody spectrum in western world

S Moghadam-Kia, CV Oddis, R Aggarwal - Current Rheumatology Reports, 2018 - Springer
Purpose of Review Anti-melanoma differentiation-associated gene 5 (anti-MDA5) is a novel
and highly specific myositis-associated autoantibody, which defines a unique phenotype …